Former Board Member Files to Sell Additional $335K in Clene Inc. Shares, Continuing Distribution Trend
Summary
A former board member of Clene Inc. has filed a Form 144 indicating intent to sell an additional $335,804 worth of common stock, extending a recent pattern of insider share distribution amidst the company's going concern warning.
Key Events
-
Intent to Sell Additional Shares
Symbiosis II LLC, a former board member, filed a Form 144 to sell 56,916 shares of Clene Inc. common stock, valued at approximately $335,804.00.
-
Continuation of Insider Distribution
This filing extends a recent pattern of significant insider selling, with Symbiosis II LLC having already sold 291,980 shares for gross proceeds of $1,560,394.90 in the past three months.
-
Context of Financial Uncertainty
The ongoing insider sales occur against the backdrop of Clene Inc.'s last annual report (2026-03-17), which raised substantial doubt about the company's ability to continue as a going concern.
Analysis
This Form 144 filing indicates a continued intent by a former board member, Symbiosis II LLC, to liquidate a significant portion of their holdings in Clene Inc. The proposed sale of over $335,000 worth of shares, following nearly $1.6 million in sales over the past three months, reinforces a clear pattern of insider distribution. This ongoing selling pressure from a key insider is particularly notable given the company's recent disclosure of substantial doubt about its ability to continue as a going concern, as highlighted in its last annual report. Investors should view this as a negative signal regarding insider confidence and potential future stock overhang.
At the time of this filing, CLNN was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.